153 related articles for article (PubMed ID: 24006142)
1. Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.
Yi JS; Decroos EC; Sanders DB; Weinhold KJ; Guptill JT
Muscle Nerve; 2013 Dec; 48(6):992-3. PubMed ID: 24006142
[No Abstract] [Full Text] [Related]
2. Use and monitoring of low dose rituximab in myasthenia gravis.
Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.
Stein B; Bird SJ
J Clin Neuromuscul Dis; 2011 Mar; 12(3):163-4. PubMed ID: 21321497
[No Abstract] [Full Text] [Related]
4. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.
Keung B; Robeson KR; DiCapua DB; Rosen JB; O'Connor KC; Goldstein JM; Nowak RJ
J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1407-9. PubMed ID: 23761915
[No Abstract] [Full Text] [Related]
5. Rituximab treatment of myasthenia gravis: A systematic review.
Tandan R; Hehir MK; Waheed W; Howard DB
Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
[TBL] [Abstract][Full Text] [Related]
6. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
[TBL] [Abstract][Full Text] [Related]
7. Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.
Kuntzer T; Carota A; Novy J; Cavassini M; Du Pasquier RA
Neurology; 2011 Feb; 76(8):757-8. PubMed ID: 21339503
[No Abstract] [Full Text] [Related]
8. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.
Hain B; Jordan K; Deschauer M; Zierz S
Muscle Nerve; 2006 Apr; 33(4):575-80. PubMed ID: 16323216
[TBL] [Abstract][Full Text] [Related]
9. [Proposal for rituximab treatment in patients with myasthenia gravis].
Konno S
Rinsho Shinkeigaku; 2013; 53(11):1312-4. PubMed ID: 24291971
[TBL] [Abstract][Full Text] [Related]
10. Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action.
Salvi M; Vannucchi G; Currò N; Introna M; Rossi S; Bonara P; Covelli D; Dazzi D; Guastella C; Pignataro L; Ratiglia R; Golay J; Beck-Peccoz P
Arch Ophthalmol; 2012 Jan; 130(1):122-4. PubMed ID: 22232486
[No Abstract] [Full Text] [Related]
11. Rituximab in refractory MuSK antibody myasthenia gravis.
Thakre M; Inshasi J; Marashi M
J Neurol; 2007 Jul; 254(7):968-9. PubMed ID: 17468964
[No Abstract] [Full Text] [Related]
12. Rituximab in refractory myasthenia gravis: Extended prospective study results.
Beecher G; Anderson D; Siddiqi ZA
Muscle Nerve; 2018 Sep; 58(3):452-455. PubMed ID: 29742795
[TBL] [Abstract][Full Text] [Related]
13. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
Weger S; Appendino JP; Clark IH
J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
[TBL] [Abstract][Full Text] [Related]
14. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.
Stathopoulos P; Kumar A; Nowak RJ; O'Connor KC
JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878127
[TBL] [Abstract][Full Text] [Related]
15. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.
Zhou Y; Yan C; Gu X; Zhou L; Lu J; Zhu W; Huan X; Luo S; Zhong H; Lin J; Lu J; Zhao C; Xi J
Muscle Nerve; 2021 Jun; 63(6):824-830. PubMed ID: 33745138
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature.
Koul R; Al Futaisi A; Abdwani R
Pediatr Neurol; 2012 Sep; 47(3):209-12. PubMed ID: 22883288
[TBL] [Abstract][Full Text] [Related]
17. Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
Li H; Huang Z; Jia D; Xue H; Pan J; Zhang M; Shi K; Shi FD; Zhang C
J Neuroimmunol; 2021 May; 354():577528. PubMed ID: 33662696
[TBL] [Abstract][Full Text] [Related]
18. Memory B cell resurgence requires repeated rituximab in myasthenia gravis.
Muto K; Matsui N; Unai Y; Sakai W; Haji S; Udaka K; Miki H; Furukawa T; Abe M; Kaji R
Neuromuscul Disord; 2017 Oct; 27(10):918-922. PubMed ID: 28694074
[TBL] [Abstract][Full Text] [Related]
19. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
[TBL] [Abstract][Full Text] [Related]
20. Infantile onset myasthenia gravis with MuSK antibodies.
Murai H; Noda T; Himeno E; Kawano Y; Ohyagi Y; Shiraishi H; Motomura M; Kira J
Neurology; 2006 Jul; 67(1):174. PubMed ID: 16832105
[No Abstract] [Full Text] [Related]
[Next] [New Search]
